Patents by Inventor E. Sally Ward

E. Sally Ward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10519247
    Abstract: The disclosure provides monoclonal bispecific antibodies targeting HER2 and HER3. The disclosure also provides monospecific tetravalent HER3 antigen binding antibodies. Still further provided by the disclosure are methods of treating a cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antibody provided by the disclosure.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: December 31, 2019
    Assignee: Board of Regents,The University of Texas System
    Inventors: E. Sally Ward, Raimund Ober, Jeffrey Kang, Jayakumar Poovassery
  • Patent number: 10345310
    Abstract: Disclosed are methods of identifying tumor-derived exosomes as an early cancer diagnostic, as well as for staging, assessing progression and assessing therapy of cancer.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: July 9, 2019
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Alan Schroit, Adi Gazdar, E. Sally Ward Ober
  • Patent number: 10316073
    Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
    Type: Grant
    Filed: December 23, 2014
    Date of Patent: June 11, 2019
    Assignees: argenx BVBA, The Board of Regents of the University of Texas System
    Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
  • Publication number: 20180179258
    Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
    Type: Application
    Filed: November 22, 2017
    Publication date: June 28, 2018
    Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
  • Publication number: 20170334962
    Abstract: The invention disclosed herein generally relates to fusion proteins for use alone or as adjuvants or antigen delivery vehicles for vaccines.
    Type: Application
    Filed: May 19, 2017
    Publication date: November 23, 2017
    Inventors: E. Sally Ward Ober, Dilip K. Challa
  • Publication number: 20170146542
    Abstract: Disclosed are methods of identifying tumor-derived exosomes as an early cancer diagnostic, as well as for staging, assessing progression and assessing therapy of cancer.
    Type: Application
    Filed: June 9, 2016
    Publication date: May 25, 2017
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Alan SCHROIT, Adi GAZDAR, E. Sally WARD OBER
  • Publication number: 20160229920
    Abstract: The disclosure provides monoclonal bispecific antibodies targeting HER2 and HER3. The disclosure also provides monospecific tetravalent HER3 antigen binding antibodies. Still further provided by the disclosure are methods of treating a cancer in a subject, comprising administering to the subject a therapeutically effective amount of an antibody provided by the disclosure.
    Type: Application
    Filed: October 31, 2014
    Publication date: August 11, 2016
    Inventors: E. Sally Ward, Raimund Ober, Jeffrey Kang, Jayakumar Poovassery
  • Publication number: 20150218239
    Abstract: Provided are novel FcRn antagonist compositions comprising a variant Fc region that binds specifically to FcRn with increased affinity and reduced pH dependence relative to the native Fc region. Also provided are FcRn antagonists with enhanced CD16 binding affinity. Also provided are methods of treating antibody-mediated disorders (e.g. autoimmune diseases) using the these FcRn antagonist compositions, nucleic acids encoding the FcRn antagonist compositions, recombinant expression vectors and host cells for making the FcRn antagonist compositions, and pharmaceutical compositions comprising the FcRn antagonist compositions.
    Type: Application
    Filed: December 23, 2014
    Publication date: August 6, 2015
    Applicants: arGEN-X B.V., The Board of Regents of the University of Texas System
    Inventors: Peter Ulrichts, Christophe Blanchetot, Torsten Dreier, Johannes de Haard, E. Sally Ward Ober, Nicolas G. H. Ongenae
  • Patent number: 8834871
    Abstract: The present invention provides for IgG1 molecules with improved characteristics. In particular, substitution mutations are provided that, in combination, facilitate improved placental transfer, improved serum half-life and improved FcRn binding. Substitution mutations are also provided, that in combination, can be used to block FcRn function and thereby increase the clearance rates of other (endogenous or exogenous) IgGs, block placental transport of IgGs and have increased affinity/reduced pH dependence for FcRn binding.
    Type: Grant
    Filed: March 27, 2012
    Date of Patent: September 16, 2014
    Assignee: The Board of the University of Texas System
    Inventor: E. Sally Ward Ober
  • Publication number: 20120195892
    Abstract: The present invention provides for IgG1 molecules with improved characteristics. In particular, substitution mutations are provided that, in combination, facilitate improved placental transfer, improved serum half-life and improved FcRn binding. Substitution mutations are also provided, that in combination, can be used to block FcRn function and thereby increase the clearance rates of other (endogenous or exogenous) IgGs, block placental transport of IgGs and have increased affinity/reduced pH dependence for FcRn binding.
    Type: Application
    Filed: March 27, 2012
    Publication date: August 2, 2012
    Inventor: E. SALLY WARD OBER
  • Patent number: 8163881
    Abstract: The present invention provides for IgG1 molecules with improved characteristics. In particular, substitution mutations are provided that, in combination, facilitate improved placental transfer, improved serum half-life and improved FcRn binding. Substitution mutations are also provided, that in combination, can be used to block FcRn function and thereby increase the clearance rates of other (endogenous or exogenous) IgGs, block placental transport of IgGs and have increased affinity/reduced pH dependence for FcRn binding.
    Type: Grant
    Filed: May 31, 2006
    Date of Patent: April 24, 2012
    Assignee: The Board of Regents of the University of Texas System
    Inventor: E. Sally Ward Ober
  • Patent number: 6165745
    Abstract: Disclosed are recombinant vectors encoding immunoglobulin-like domains and portions thereof, such as T-cell variable domains, antibody Fc-hinge fragments, subfragments and mutant domains with reduced biological half lives. Methods of producing large quantities of such domains, heterodimers, and fusion proteins following expression and secretion by prokaryotic host cells are also reported. Described are single chain T-cell receptors, which are folded into .beta.-pleated sheet structures similar to those of immunoglobulin variable domains; antibody Fc and Fc-hinge domains, which have the same in vivo stability as intact antibodies; and domains engineered to have reduced half lives.
    Type: Grant
    Filed: November 17, 1994
    Date of Patent: December 26, 2000
    Assignee: Board of Regents, The University of Texas System
    Inventors: E. Sally Ward, Jin-Kyoo Kim